Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: A randomized phase III clinical trial

Journal of Clinical Oncology

Volumn 26, Issue 14, 2008, Pages 2285-2291

  Ravaud, Alain ^a   Hawkins, Robert ^b   Gardner, Jason P ^b   Von Der Maase, Hans ^b   Zantl, Niko ^b   Harper, Peter ^b   Rolland, Frédéric ^b   Audhuy, Bruno ^b   Machiels, Jean Pascal ^b   Pétavy, Frank ^b   Gore, Martin ^b   Schöffski, Patrick ^b   El Hariry, Iman ^b  

^a HÔPITAL SAINT ANDRÉ   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MEGESTROL ACETATE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROSIS; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; HAZARD RATIO; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; OPEN STUDY; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMATITIS; VASCULAR DISEASE; VOMITING; BIOSYNTHESIS; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; ENZYMOLOGY; KIDNEY TUMOR; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MEGESTROL ACETATE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAMOXIFEN;

EID: 44249127263     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.5029     Document Type: Article

References (26)

1. Lipworth T, Tarone RE, McLaughin JK: The epidemiology of renal cell carcinoma. J Urol 176:2353-2358, 2006
2. Rohrmann K, Staehler M, Haseke N, et al: Immunotherapy in metastatic renal cell carcinoma. World J Urol 23:196-201, 2005
3. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007
4. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007
5. Moch H, Sauter G, Buchholz N, et al: Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 28:1255-1259, 1997
6. Prewett M, Rothman M, Waksal H, et al: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 4:2957-2966, 1998
7. Merseburger AS, Hennenlotter J, Simon P, et al: Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer. Anticancer Res 25:1901-1907, 2005
8. Smith K, Gunaratnam L, Morley M, et al: Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res 65:5221-5230, 2005
9. Latif Z, Watters AD, Bartlett JM, et al: Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int 89:5-9, 2002
10. Geyer CE, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
11. Medical Research Council Renal Cancer Collaborators: Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Lancet 353:14-17, 1999
12. Atzpodien J, Hoffmann R, Franzke M, et al: Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95:1045-1050, 2002
13. Stebbing J, Benson C, Eisen T, et al: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953-958, 2001
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. National Cancer Institute: National Cancer Institute Common Toxicity Criteria version 2.0. http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf
16. Motzer RJ, Bacik J, Schwartz LH, et al: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463, 2004
17. Motzer RJ, Amato R, Todd M, et al: Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21:99-101, 2003
18. Rowinsky EK, Schwartz GH, Gollob JA, et al: Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015, 2004
19. Drucker B, Bacik J, Ginsberg M, et al: Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 21:341-345, 2003
20. Dawson NA, Guo C, Zak R, et al: A phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10:7812-7819, 2004
21. Jermann M, Stahel RA, Salzberg M, et al: A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57:533-539, 2006
22. Beeram M, Rowinsky EK, Weiss GR, et al: Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: A phase II, pharmacokinetic (PK) and biological correlative study with FDG-PET imaging. J Clin Oncol 22:207s, 2004 (suppl; abstr 3050)
23. Hainsworth JD, Sosman JA, Spigel DR, et al: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 23:7889-7896, 2005
24. Bukowski RM, Kabbinavar F, Figlin RA, et al: Randomized phase II or erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell carcinoma. J Clin Oncol 25:4536-4541, 2007
25. Stumm G, Eberwein S, Rostock-Wolf S, et al: Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis. Int J Cancer 69:17-22, 1996
26. Langner C, Ratschek M, Rehak P, et al: Steroid hormone receptor expression in renal cell carcinoma: An immunohistochemical analysis of 182 tumors. J Urol 171:611-614, 2004